4.7 Article

Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy

Journal

RADIOTHERAPY AND ONCOLOGY
Volume 171, Issue -, Pages 91-100

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.radonc.2022.04.006

Keywords

Head and neck squamous cell carcinoma; Gene signature; Postoperative radiotherapy; Hypoxia; Cancer stem cells; Machine learning

Ask authors/readers for more resources

This study developed and validated a novel prognostic 6-gene signature for predicting loco-regional control of HPV-negative HNSCC patients treated with postoperative radio(chemo)therapy. The signature showed predictive significance in both training and validation cohorts, and could improve personalized clinical trials for radiotherapy.
Purpose: The aim of this study was to develop and validate a novel gene signature from fulltranscriptome data using machine-learning approaches to predict loco-regional control (LRC) of patients with human papilloma virus (HPV)-negative locally advanced head and neck squamous cell carcinoma (HNSCC), who received postoperative radio(chemo)therapy (PORT-C).Materials and methods: Gene expression analysis was performed using Affymetrix GeneChip Human Transcriptome Array 2.0 on a multicentre retrospective training cohort of 128 patients and an independent validation cohort of 114 patients from the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Genes were filtered based on differential gene expression analyses and Cox regression. The identified gene signature was combined with clinical parameters and with previously identified genes related to stem cells and hypoxia. Technical validation was performed using nanoString technology.Results: We identified a 6-gene signature consisting of four individual genes CAV1, GPX8, IGLV3-25, TGFBI, and one metagene combining the highly correlated genes INHBA and SERPINE1. This signature was prognostic for LRC on the training data (ci = 0.84) and in validation (ci = 0.63) with a significant patient stratification into two risk groups (p = 0.005). Combining the 6-gene signature with the clinical parameters T stage and tumour localisation as well as the cancer stem cell marker CD44 and the 15-gene hypoxia-associated signature improved the validation performance (ci = 0.69, p = 0.001). Conclusion: We have developed and validated a novel prognostic 6-gene signature for LRC of HNSCC patients with HPV-negative tumours treated by PORT-C. After successful prospective validation the signature can be part of clinical trials on the individualization of radiotherapy.(c) 2022 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 171 (2022) 91-100

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available